Group 1 - The Hong Kong Stock Connect Innovative Drug ETF (工银, 159217) increased by 0.54% on February 6, with a trading volume of 601 million yuan [1] - The fund's shares rose by 66 million to a total of 3.936 billion shares, with an increase of 191 million shares over the last 20 trading days [1] - The latest net asset value of the fund is 5.088 billion yuan [1] Group 2 - The performance benchmark for the ETF is the adjusted return rate of the Guotai Junan Hong Kong Stock Connect Innovative Drug Index [1] - The fund is managed by ICBC Credit Suisse Asset Management Company, with fund managers Liu Weilin and Jiao Wendong [1] - Since its establishment on March 26, 2025, the fund has achieved a return of 29.26%, while the return over the past month is -3.95% [1]
2月6日港股通创新药ETF工银（159217）份额增加6600.00万份
Xin Lang Cai Jing·2026-02-09 01:12